Repligen Q2 revenue rises 11.9% to $204.1 million

Earnings

โดย Yahoo Finance·

Summary · why it matters

Repligen reported second-quarter revenues of $204.1 million, up 11.9% year over year and exceeding analysts' expectations by 1.1%. The company also beat analysts' EPS and organic revenue estimates, with President and CEO Olivier Loeillot citing 13% organic growth and increased full-year guidance. Among the eight drug development inputs and services stocks tracked, the group's revenues beat consensus estimates by 4.1% on average, while next quarter's revenue guidance came in 0.8% above expectations. Repligen delivered the weakest performance against analyst estimates and the weakest full-year guidance update of the group, yet its stock is up 29.4% since reporting and currently trades at $169.56. Azenta posted the best Q2 with revenues of $161.2 million, up 12% year over year and beating estimates by 8%, while IQVIA reported revenues of $4.37 billion, up 8.7% year over year and exceeding expectations by 1.5%.